Compare United States Brent Oil Fund LP (BNO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Brent Oil Fund LP vs Incyte Corporation — how do they compare? United States Brent Oil Fund LP trades at $50.83, while Incyte Corporation trades at $120.58 (market cap $24.54B). Which is the better fit depends on your goals.
| BNO | INCY | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $129.93 |
52-Week Low | $27.20 | $81.61 |
Market Cap | — | $24.54B |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNO, tracking Brent crude oil futures, trades at $50.73, up 1.24% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights supply disruptions from the Strait of Hormuz standoff and OPEC's lowered demand forecasts, creating volatility. The stock lacks traditional financial ratios as it is an ETF, with performance tied directly to oil price movements and geopolitical developments.
Outlook hinges on oil market dynamics, with upside from sustained supply risks but downside from demand weakness. Risks include Middle East tensions and inventory builds. Analysts monitor EIA data and OPEC actions for direction, with current sentiment mixed amid headline-driven price swings.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
